So Far, Not So Good: Neurologists Slow to Warm Up to Biogen’s Alzheimer Drug Aduhelm, Study Finds
From: FiercePharma By: Beth Snyder Bulik While almost 90% of neurologists are moderately or highly aware of Aduhelm, only 3% have written prescriptions so far, according to Spherix Global Insights latest data…(read more)
Initial Launch Execution Fails to Impress for Biogen’s Aduhelm – the First-to-Market Disease-Modifying Therapy for the Treatment of Alzheimer’s Disease – as the Controversy Churn Continues
One month post launch, Spherix data indicates that Aduhelm (aducanumab-avwa) awareness easily outpaces other key performance indicators, including degree of advance, anticipated patient candidacy, prescriber uptake, and launch execution among US neurologists EXTON, Pa., July 14, 2021/PRNewswire/ — As expected with the recent media maelstrom surrounding its June 7th approval, unaided and aided awareness of […]
As GSK, Aurinia Heat up the Lupus Nephritis Category, Analyst Gauges Doctors’ First Impressions
From: FiercePharma By: Beth Snyder Bulik The lupus nephritis category is sporting a first-ever brand battle—two new-to-category drugs with very different profiles and marketing strategies…(read more).
What Has the Evolution of Ocrevus Taught You About the MS Market? Here’s What I’ve Learned…
By: Virginia Schobel June 9, 2021 – My name is Virginia Schobel and I’m the Neurology Franchise Head at Spherix Global Insights. I have spent the last 20 years monitoring and analyzing the multiple sclerosis (MS) markets in the United States, Canada, and Europe both on the client and vendor side – most […]
Use of Takeda’s Entyvio SC in Inflammatory Bowel Disease Has Slowed Considerably in the EU5 as Gastroenterologists Eye Potential New Launches Later This Year
Spherix finds that perceptions related to efficacy appear to be impacting the new, more convenient formulation of the α4β7 integrin inhibitor just as Gilead/Galapagos’ filgotinib gains traction among pipeline therapies EXTON, Pa., June 8, 2021 /PRNewswire – A few months after the European Medicines Agency (EMA) approved Takeda’s subcutaneous formulation of Entyvio, known as Entyvio […]
Early Experiences and Perceptions of Recently Approved Lupus Nephritis Products BENLYSTA (GlaxoSmithKline) and LUPKYNIS (Aurinia) Begin to Drive Increased Prescribing Among Nephrologists and Rheumatologists
After several months on the market to treat lupus nephritis, uptake and prescribing patterns of Benlysta and Lupkynis reveal nephrologists and rheumatologists are approaching the new products from different perspectives EXTON, Pa., June 8, 2021 /PRNewswire/ — The Lupus Foundation of America estimates that 1.5 million Americans, and at least five million people worldwide, have a […]
Physician Assessment of Patients’ COVID-19 Risk and Impact on Lasmiditan, Ubrogepant, or Rimegepant Prescription Decisions: Analysis from a Cross-Sectional, Retrospective US Patient Chart Audit
Authors: Shirley Ju, MD; Vanessa Cooper, MD; P. Christopher H. Gottschalk, MD, FAHS; Virginia R. Schobel, MSc SUMMARY: Examine patient characteristics that influence physicians’ perceptions of patient COVID-19 risk and how such risk categorizations influence acute migraine therapy selection. BACKGROUND: Many factors influence prescribers’ decisions, including familiarity with treatment options and assessment of risk. In […]
Selection Drivers for Recently Prescribed Lasmiditan, Ubrogepant, or Rimegepant for the Acute Treatment of Migraine: Results from an Annual Cross-Sectional Patient Chart Audit in the United States
Authors: Virginia R. Schobel, MSc SUMMARY: Influential drivers of the decision to prescribe the newly approved therapies for the acute treatment of migraine differ more within the gepant class than between the gepant and ditan classes, according to a retrospective, cross-sectional patient chart review audit. BACKGROUND: In 2020, pharmaceutical options for acute management of migraine […]
Mayzent, Zeposia May Lose Ground in Canada, Report Finds
From: Multiple Sclerosis News Today By: Marta Figueiredo, PhD Mayzent (siponimod) and Zeposia (ozanimod), the two sphingosine-1-phosphate (S1P) receptor modulators most recently approved in Canada for treating multiple sclerosis (MS), showed strong launches in the country, according to the latest Spherix Global Insights’ report…(read more).
Bristol Myers Squibb’s Zeposia and Novartis’ Mayzent Have Both Experienced Strong Launches in Canada, But Spherix Data Uncover Numerous Internal and External Threats for Sustained Success
Neurologists in Canada are receptive to having a fourth S1P receptor modulator option in Janssen’s Ponvory, although increasing the clinical relevance of the agent’s comparative efficacy to Sanofi Genzyme’s Aubagio and fatigue secondary endpoint data is a must for any notable uptake EXTON, Pa., May 25, 2021/PRNewswire – Over the past two years, two new […]
